Suchergebnisse - "van Maanen, Rob"

PubPharm (25)

1

Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA) : a randomized, placebo-controlled, phase 2/3 trial

enthalten in: EClinicalMedicine | 2024

von Lobo, S. | Plantefève, G. | Nair, G. | +48

2

Challenges in developing Geroscience trials

enthalten in: Nature communications | 2023

von Rolland, Y. | Sierra, F. | Ferrucci, L. | +48

3

Novel Potential Targets for Function-Promoting Therapies : Orphan Nuclear Receptors, Anti-inflammatory Drugs, Troponin Activators, Mas Receptor Agonists, and Urolithin A

enthalten in: The journals of gerontology. Series A, Biological sciences and medical sciences | 2023

von Dioh, W. | Narkar, V. | Singh, A. | +6

4

Assessment and Management of Appetite Loss in Older Adults: An ICFSR Task Force Report

enthalten in: The journal of Frailty & Aging | 2022

von de Souto Barreto, P. | Cesari, M. | Morley, J. | +26

5

Assessment and Management of Appetite Loss in Older Adults: An ICFSR Task Force Report

enthalten in: The journal of Frailty & Aging | 2022

von de Souto Barreto, P. | Cesari, M. | Morley, J. | +26

6

Resilience: Biological Basis and Clinical Significance — A Perspective Report from the International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force

enthalten in: The journal of Frailty & Aging | 2022

von Cesari, M. | Azzolino, D. | LeBrasseur, N. | +27

7

A randomised placebo-controlled, double-blind phase II study to explore the safety, efficacy, and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease and motor symptoms ("KHENERGYC")

enthalten in: BMC neurology | 2022

von Smeitink, J. | van Maanen, R. | de Boer, L. | +2

8

A randomised placebo-controlled, double-blind phase II study to explore the safety, efficacy, and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease and motor symptoms (“KHENERGYC”)

enthalten in: BMC neurology | 2022

von Smeitink, J. | van Maanen, R. | de Boer, L. | +2

9

A randomised placebo-controlled, double-blind phase II study to explore the safety, efficacy, and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease and motor symptoms (“KHENERGYC”)

enthalten in: BMC neurology | 2022

von Smeitink, J. | van Maanen, R. | de Boer, L. | +2

10

Community Consensus Guidelines to Support FAIR Data Standards in Clinical Research Studies in Primary Mitochondrial Disease

enthalten in: Advanced genetics (Hoboken, N.J.) | 2022

von Karaa, A. | MacMullen, L. | Campbell, J. | +13